SUMO2 Gene: Small Ubiquitin-Like Modifier 2
Essential regulator of protein SUMOylation, implicated in cellular stress response, genome stability, and disease.
Gene Information Card
| Symbol | SUMO2 |
|---|---|
| Full Name | Small Ubiquitin-Like Modifier 2 |
| Gene Type | Protein coding |
| Chromosomal Location | 17q25.1 |
| NCBI Gene ID | 6613 ncbi.nlm.nih.gov/gene/6613 |
| Ensembl ID | ENSG00000188612 |
| UniProt ID | P61956 |
| OMIM ID | 603042 |
| HGNC ID | 11125 |
| Aliases | SMT3A, SMT3H2, SUMO3 (obsolete) |
Description
The SUMO2 gene encodes a member of the small ubiquitin-like modifier (SUMO) protein family. SUMO2 is conjugated to target proteins in a process called SUMOylation, a post-translational modification that regulates protein function, localization, and stability. SUMO2 shares high sequence similarity with SUMO3 and can form poly-SUMO chains, which are critical for cellular stress responses, DNA damage repair, and cell cycle control. SUMO2 is ubiquitously expressed and plays a key role in maintaining genome integrity and cellular homeostasis.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Cancer (various types) | Dysregulation of SUMO2 expression or SUMOylation machinery can alter oncogenic pathways, affecting cell proliferation and apoptosis. | COSMIC; PubMed studies (e.g., PMID: 25642765) |
| Neurodegenerative disorders (e.g., Alzheimer's disease) | SUMO2 modification of tau and other proteins may influence protein aggregation and neurotoxicity. | PubMed (e.g., PMID: 24009748) |
| Cardiovascular diseases | SUMO2-mediated SUMOylation of cardiac proteins affects stress responses and cardiac hypertrophy. | PubMed (e.g., PMID: 23455335) |
| Infectious diseases | Some viruses exploit SUMO2 to modulate host immune responses. | PubMed (e.g., PMID: 26018192) |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Brain | 15.2 | Medium |
| Heart | 12.8 | Medium |
| Liver | 10.5 | Low |
| Kidney | 11.3 | Medium |
| Testis | 18.9 | High |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HeLa | 14.5 | Cervical cancer cell line; high expression |
| HEK293 | 13.2 | Embryonic kidney cells; moderate expression |
| HepG2 | 10.1 | Liver cancer cell line; low expression |
| K562 | 16.7 | Leukemia cell line; high expression |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.163A>G (p.Thr55Ala) | Missense | Rare | May affect SUMO2 stability or function; clinical significance unknown |
| c.214G>A (p.Val72Ile) | Missense | Rare | Potential impact on protein interactions; not well characterized |
| Copy number alterations | CNV | Variable | Amplifications or deletions observed in some cancers; may contribute to tumorigenesis |
Mutation functional classification
Loss of Function (LOF)
Loss-of-function mutations in SUMO2 are rare and may impair SUMOylation capacity, leading to defects in DNA repair and cell cycle regulation, potentially contributing to genomic instability.
Gain of Function (GOF)
Gain-of-function mutations that increase SUMO2 expression or enhance its conjugation activity could promote oncogenic signaling by stabilizing tumor-promoting proteins.
Dominant Negative (DN)
Dominant-negative mutations might interfere with SUMO2 incorporation into poly-SUMO chains, disrupting normal SUMOylation dynamics and downstream signaling.
View complete mutation data：
Gene Ontology (GO)
Pathways
• SUMOylation pathway
• DNA damage response
• Cell cycle regulation
• p53 signaling pathway
Protein Summary
SUMO2 is a 95-amino acid protein that is post-translationally processed to its mature form. It is conjugated to target proteins via an isopeptide bond, often forming poly-SUMO chains. SUMO2 shares ~97% sequence identity with SUMO3 but differs from SUMO1. SUMO2 is involved in stress-induced SUMOylation, where it rapidly conjugates to many nuclear proteins upon heat shock or oxidative stress. It plays critical roles in transcriptional regulation, DNA repair, and maintenance of genome stability. Dysregulation of SUMO2 has been linked to various diseases, including cancer and neurodegeneration.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| SUMO2 Knockout HEK293 Cell Line | EDJ-KQ50642 | Human | 6613 | Details Get a Quote |
| SUMO2 Knockout HeLa Cell Line | EDJ-KQ54530 | Human | 6613 | Details Get a Quote |
| SUMO2 Knockout A-549 Cell Line | EDJ-KQ63013 | Human | 6613 | Details Get a Quote |
| SUMO2 Knockout HCT 116 Cell Line | EDJ-KQ71488 | Human | 6613 | Details Get a Quote |
| SUMO2 Knockout HEK293T Cell Line | EDC90776 | Human | 6613 | Details Get a Quote |
